A major observational study has identified an unexpected protective association between GLP-1 receptor agonists and breast cancer development in women. The medications—commonly known by brand names including Ozempic, Wegovy, Mounjaro, and Zepbound—demonstrated approximately 30% lower breast cancer rates compared to non-users, representing a substantial effect size that has garnered significant attention from oncology researchers.
Originally developed for diabetes management and later approved for weight loss, GLP-1 drugs may offer benefits extending far beyond metabolic health. Researchers hypothesize that improved metabolic function and reduced insulin resistance could mediate protective effects against breast cancer. However, experts emphasize that these findings represent correlation rather than proven causation. The promising results have prompted the planning of dedicated clinical trials to rigorously test whether GLP-1 medications can serve as potential breast cancer prevention agents.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: GLP-1 Drugs Show 30% Lower Breast Cancer Risk in Major Study →
